Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation

26 Jul 2007

Abstract excerpt

This randomized, double-blinded, placebo-controlled trial examined genetic influences on treatment response to sustained-release bupropion for smoking cessation. Smokers of European ancestry (N = 291), who were randomized to receive bupropion or placebo (12 weeks) plus counseling, were genotyped for the dopamine D2 receptor (DRD2-Taq1A), dopamine transporter (SLC6A3 3' VNTR), and cytochrome P450 2B6 (CYP2B6 1459...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Smoking Behavior and Cessation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 17654295
DOI: 10.1080/14622200701382033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationPMID 17654295Read ↗

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Semantic proximity Read ↗

Pharmacogenetic investigation of smoking cessation treatment.Semantic proximity Read ↗

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.Semantic proximity Read ↗

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.Semantic proximity Read ↗

Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers.Semantic proximity Read ↗

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Semantic proximity Read ↗

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.Semantic proximity Read ↗

Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence.Semantic proximity Read ↗

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.